Lina Ya'Qoub1, Islam Y Elgendy2, Carl J Pepine3. 1. Division of Interventional Cardiology, Henry Ford Hospital, Detroit, MI, USA. 2. Department of Medicine, Weill Cornell Medicine-Qatar, Doha, Qatar. 3. Division of Cardiovascular Medicine, University of Florida, 1329 SW 16th St, PO Box 100288, Gainesville, FL, USA. carl.pepine@medicine.ufl.edu.
Abstract
PURPOSE OF REVIEW: A significant proportion of patients evaluated for chest pain have ischemia with non-obstructive coronary artery disease (INOCA). Studies have shown INOCA is associated with increased risk of major adverse cardiac events and significant burden on the health care system. RECENT FINDINGS: While there is scarce scientific evidence on management of INOCA, the CorMicA trial showed that stratified medical therapy based on the type of INOCA improved patients' symptoms and quality of life. There are multiple ongoing trials, including Women's IschemiA Trial to Reduce Events in Non-ObstRuctIve CORonary Artery Disease (WARRIOR trial), assessing the benefit of intensive medical therapy versus usual care for this increasingly recognized clinical entity. In this review, we discuss the definition of INOCA, epidemiology and risk factors, pathophysiology, and management as well as the current knowledge gaps and ongoing clinical trials in this arena.
PURPOSE OF REVIEW: A significant proportion of patients evaluated for chest pain have ischemia with non-obstructive coronary artery disease (INOCA). Studies have shown INOCA is associated with increased risk of major adverse cardiac events and significant burden on the health care system. RECENT FINDINGS: While there is scarce scientific evidence on management of INOCA, the CorMicA trial showed that stratified medical therapy based on the type of INOCA improved patients' symptoms and quality of life. There are multiple ongoing trials, including Women's IschemiA Trial to Reduce Events in Non-ObstRuctIve CORonary Artery Disease (WARRIOR trial), assessing the benefit of intensive medical therapy versus usual care for this increasingly recognized clinical entity. In this review, we discuss the definition of INOCA, epidemiology and risk factors, pathophysiology, and management as well as the current knowledge gaps and ongoing clinical trials in this arena.
Authors: Hernán Mejía-Rentería; Nina van der Hoeven; Tim P van de Hoef; Julius Heemelaar; Nicola Ryan; Amir Lerman; Niels van Royen; Javier Escaned Journal: Int J Cardiovasc Imaging Date: 2017-05-13 Impact factor: 2.357
Authors: Sherif A Sakr; Tarek M Abbas; Maged Z Amer; Eid M Dawood; Nader El-Shahat; Ibraheim A Abdel Aal; Mahmoud M Ramadan Journal: Int Heart J Date: 2009-07 Impact factor: 1.862
Authors: Manesh R Patel; David Dai; Adrian F Hernandez; Pamela S Douglas; John Messenger; Kirk N Garratt; Thomas M Maddox; Eric D Peterson; Matthew T Roe Journal: Am Heart J Date: 2014-03-14 Impact factor: 4.749
Authors: Haseeb Rahman; Ozan M Demir; Faisal Khan; Matthew Ryan; Howard Ellis; Mark T Mills; Amedeo Chiribiri; Andrew Webb; Divaka Perera Journal: J Am Coll Cardiol Date: 2020-05-26 Impact factor: 24.094
Authors: Paul D Morris; Rebecca Gosling; Iwona Zwierzak; Holli Evans; Louise Aubiniere-Robb; Krzysztof Czechowicz; Paul C Evans; D Rodney Hose; Patricia V Lawford; Andrew J Narracott; Julian P Gunn Journal: Cardiovasc Res Date: 2021-05-25 Impact factor: 13.081